Santhosh Sethumadhavan, Anandan Rangasamy, Sini Theruvathil K, Mathew Paruthapara T
Fish Processing Division, Central Institute of Fisheries Technology, Cochin, India.
J Gastroenterol Hepatol. 2007 Jun;22(6):949-53. doi: 10.1111/j.1440-1746.2007.04840.x. Epub 2007 May 14.
Helicobacter pylori is the major causative factor of ulcer but the use of ibuprofen and other non-steroidal anti-inflammatory drugs have also been implicated in development of ulcer. The purpose of the present study was to determine the anti-ulcer effect of glucosamine.
The protective effect of glucosamine on ibuprofen-induced peptic ulcer in male albino rats was studied with respect to changes in the volume of gastric juice, acid output, pepsin activity, activities of membrane bound ATPases, protein content, glycoprotein components and histopathology.
Oral administration of ibuprofen caused significant increase in the number of lesions in the gastric mucosa, increases in the volume of gastric juice and acidity, and decreased activity of pepsin. The levels of protein content and glycoprotein components (hexose, hexosamine and sialic acid) and ATPase activities were also observed. Oral pretreatment with glucosamine resulted in significant reduction in the number of lesions in the gastric mucosa and decreases in the volume of gastric juice and acidity. The pepsin activity was also maintained at near normalcy. Prior oral administration of glucosamine significantly prevented the ibuprofen-induced depletion of protein and glycoprotein components and maintained the activities of membrane bound ATPases as compared to untreated ulcer induced group of rats.
The anti-ulcerogenic activity of glucosamine might be ascribable to its ability to neutralize the hydrochloric acid secreted into the stomach and to its capability to strengthen the mucosal barrier by increasing mucosal glycoprotein synthesis and to its free radical scavenging property. Histopathological investigations of the mucosal tissue also support the anti-ulcerogenic effect of glucosamine.
幽门螺杆菌是溃疡的主要致病因素,但布洛芬和其他非甾体类抗炎药的使用也与溃疡的发生有关。本研究的目的是确定氨基葡萄糖的抗溃疡作用。
研究了氨基葡萄糖对雄性白化大鼠布洛芬诱导的消化性溃疡的保护作用,观察指标包括胃液体积、酸分泌量、胃蛋白酶活性、膜结合ATP酶活性、蛋白质含量、糖蛋白成分及组织病理学变化。
口服布洛芬导致胃黏膜损伤数量显著增加,胃液体积和酸度升高,胃蛋白酶活性降低。同时观察到蛋白质含量、糖蛋白成分(己糖、氨基己糖和唾液酸)水平及ATP酶活性的变化。口服氨基葡萄糖预处理可显著减少胃黏膜损伤数量,降低胃液体积和酸度。胃蛋白酶活性也维持在接近正常水平。与未治疗的溃疡诱导组大鼠相比,预先口服氨基葡萄糖可显著防止布洛芬诱导的蛋白质和糖蛋白成分耗竭,并维持膜结合ATP酶的活性。
氨基葡萄糖的抗溃疡活性可能归因于其中和分泌到胃内盐酸的能力、通过增加黏膜糖蛋白合成来加强黏膜屏障的能力以及其自由基清除特性。黏膜组织的组织病理学研究也支持氨基葡萄糖的抗溃疡作用。